Background-HIV is present in broncho-
Relation of HIV-I in bronchoalveolar lavage cells to Corrections for ethnicity were made where appropriate. At routine fibreoptic bronchoscopy performed by an experienced bronchoscopist, bronchoalveolar lavage (BAL) with warmed sterile saline was performed in the right middle lobe for diagnostic cytology and for bacteriological and virological culture. A 25 ml aliquot of BAL was obtained for this study and a 20 ml sample of venous blood was taken at the time of bronchoscopy for comparison with BAL cells. Pneumocystis pneumonia was diagnosed on the basis of finding the cyst form of Pneumocystis carinii in the Grocott stained sediment of BAL samples or the trophozoite form with Giemsa stain. Local ethics committee approval for the study was obtained, and informed consent was obtained from each patient before the study.
For HIV-I detection and viral isolation (with full standard laboratory precautions in a category 3 facility) the BAL sample was centrifuged at 1500 g (MSE Mistral 1000, Leicester, UK) for 15 minutes to deposit cells. The supernatant liquid was discarded and the cells were washed twice in serum free RPMI-1640 cell culture medium (Flow Laboratories, Rickmansworth, UK) containing fungizone (50 ,ug/ml). Cells in BAL fluid were then counted and viability (>98%) was checked with trypan blue. Two million cells were then seeded into each well of six well cell culture plates (Sterilin, Hounslow, UK). The cells were stimulated with 1 ,ug/ml phytohaemagglutinin (PHA-L) and 500 units/ml recombinant interleukin-2 (MRC AIDS Directed Programme Repository, Potters Bar, Hertfordshire, UK). To each culture 2 x 106 PHA stimulated cord blood leucocytes were added with a further 5 ml RPMI-1640 medium (Flow Laboratories, Rickmansworth, UK) containing 10% fetal calf serum, 1'68 g/l sodium bicarbonate, 100 ,ug/ml penicillin, 100 ,ug/ml streptomycin, and 50 ,ug/ml nystatin. Peripheral blood leucocytes were prepared from each patient by Ficoll-Hypaque centrifugation and separation, and treated in the same manner as BAL cells.
The polymerase chain reaction analysis for the detection of HIV-I proviral DNA was carried out on samples from all 157 patients, with oligonucleotide primers to the gag and reverse transcriptase regions of the HIV-I genome as previously described.3 A rigorous technique was employed to avoid cross contamination and in each experiment DNA amplified from a cell line not infected by HIV was run as a negative control. For polymerase chain reaction analysis, the BAL and peripheral blood leucocyte cell populations were divided into adherent (macrophage or monocyte enriched, 98% of cells were positive for non-specific esterase staining) and nonadherent (macrophage or monocyte depleted) cell fractions by a plastic adherence step of 18 hours in one well of a six well plate. The attempted isolation of HIV by cocultivation for 100 patients in this study was done by culturing patients' leucocytes from BAL or peripheral blood with cord blood leucocytes. The cultures were incubated in an atmosphere of 5% carbon dioxide for 28 days. On the first day and thereafter twice weekly the cultures were examined microscopically for a cytopathic effect. Two ml of culture supernatant were carefully removed, 1 ml was stored at -20°C for virological examination for p24 antigen and reverse transcriptase assays, and 1 ml was stored in the gaseous phase of liquid nitrogen for further analysis. The p24 antigen enzyme immunoassay and reverse transcriptase assays were undertaken as previously described.'4 15 Statistical comparisons were made using the x2 test and Student's t test.
Results
Polymerase chain reaction analysis for the detection of HIV-I proviral DNA was carried out on the peripheral blood and BAL cells from all 157 patients and cocultivation analysis for the detection of productive HIV-I virus infection was carried out in 100 of the 157 patients. Table 1 shows the results. HIV-I was detected by the polymerase chain reaction in 149 of 157 (95%) of the non-adherent fraction of peripheral blood containing the CD4+ lymphocyte enriched fraction and in 82 of 157 (52%) of the adherent peripheral blood leucocyte population (monocyte en-riched). In eight patients HIV could not be detected by the polymerase chain reaction in the peripheral blood non-adherent cell fraction; five of these patients had been on long term AZT treatment (>three months) and in the remaining three there were no detectable CD4 + lymphocytes in the peripheral blood leucocyte non-adherent cell fraction. HIV-I proviral DNA was detected in 83 out of 157 (53%) of non-adherent BAL cell fractions and in 80 out of 157 (51%) of the purified alveolar macrophage samples. Overall HIV-I proviral DNA was detected in one or other of the BAL cell fractions from 102 out of 157 (65%) patients. With in vitro cocultivation, productive HIV-I infection was shown in peripheral blood leucocytes from 52 of 100 patients and BAL from 59 of 100 patients. Table 2 shows the relation between the detection of HIV-I proviral DNA by the polymerase chain reaction and lung function tests. There was no difference in any lung function test between patients in whom HIV could be detected in BAL and those in whom it could not. Table 3 shows the relation between the isolation of HIV-I by cocultivation from BAL NAd-Non-adherent cells; Ad-adherent cells.
There was no statistically significant relation between presence or absence of HIV and PCP or non-PCP pneumonic illness. out HIV detected in cell fractions of BAL by the polymerase chain reaction. The presence of HIV had no additional effect on TLCo in any patient group.
Discussion
In the present study we have confirmed and extended the findings that HIV-I can be detected in bronchoalveolar lavage cell populations of some but not all HIV seropositive patients and that the presence of HIV-I can be shown both by the polymerase chain reaction to detect proviral DNA and by cocultivation in vitro to demonstrate productive viral infection. 313 We next asked two questions: does the presence or absence of HIV-I in bronchoalveolar lavage cells have any influence on abnormalities of pulmonary function or does the presence of the virus predispose to opportunistic lung infections, in particular Pneumocystis pneumonia. We first used the polymerase chain reaction to detect proviral DNA and found that 65% of our patients had HIV detectable in one or other of their BAL cell fractions. We were thus able to look at our two patient groups where HIV was present and absent to see if presence of the virus had any effect on pulmonary function tests, in particular TLCO, and the presence of Pneumocystis pneumonia. We found that it did not. As the polymerase chain reaction detects proviral DNA, which may represent a latent virus infection or defective viral infection incapable of replication and therefore unable to have a pathogenic effect, we next looked for the ability of HIV to be cocultured in vitro from BAL cells. We found that in 59% of our patients HIV could be recovered by culture and again we were able to look at two patient groups, where HIV was present and absent, and compare effects both on pulmonary function tests, in particular TLCO, and the presence or absence of Pneumocystis pneumonia. Again we found that the presence of HIV did not influence pulmonary function tests or the presence of Pneumocystis pneumonia. We therefore conclude that the presence of HIV-I in BAL cells does not make an additional contribution to immunosuppression to the extent that this is manifest by an increased incidence of Pneumocystis pneumonia or other respiratory illness. We also conclude that the presence of HIV-I does not make an additional contribution to the abnormalities of lung function described previously. 8 On the basis of this study it seems that the mere presence of the virus does not affect either of these features. Others have reported, however, that after seroconversion, HIV-I specific CD8 + cytotoxic lymphocytes (GTLs) appear in the lung and that this is related to the non-specific alveolitis recorded in HIV-I seropositive patients.'6 As well as the presence of HIV in the lung the presence of CTLs may also be required for pathological changes that could account for the abnormal lung function tests described in these patients.8 It seems that HIV-I specific CTLs can initiate inflammatory changes in the lung,'7 and CD8 +, D44 + CTLs can be detected in BAL in the absence of opportunistic lung infections or tumours in HIV-I seropositive patients. In one study nonspecific interstitial pneumonitis was seen in 38% of AIDS patients'8 and accounted for 32% of episodes of clinical pneumonitis in HIV-I seropositive patients. Further investigation by these workers showed that after transbronchial biopsy 11 of 23 (48%) patients had histological evidence of chronic interstitial pneumonitis. 9 Infiltrative CD8 lymphocytosis in BAL fluid has been linked to the presence of HIA-DR5 and seems to be a genetically determined host response to HIV.20 A clear causal link between the presence of CTLs specific for HIV and the generation of lung disease and ensuing abnormalities of lung function or pulmonary opportunistic infections remains to be established. If, in due course, it is, this would suggest that the host response to HIV in the lung may be important in pathogenesis as the present study shows that the mere presence of HIV in BAL fluid neither contributes to abnormalities of lung function nor predisposes to pulmonary opportunistic infections.
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Adventitia
To Egypt-with my defibrillator Prologue A wealthy Sheikh decides to invest in a major building project in his native city but, instead of using his own money, wishes to secure a large loan from a major Arab bank. He hires, as his agent and contact man, a shrewd wealthy Arab businessman whom we shall call X.
In May 1977 X was admitted to our Coronary Care Unit with an inferior myocardial infarct (Day 1). Within 30 minutes he had a cardiac arrest due to ventricular fibrillation from which he was promptly and successfully resuscitated by my junior staff. His subsequent medical progress was uneventful, but I was then informed that he was returning to Cairo by Day 11 in order to conclude a £20 million business deal. My initial reaction was to say "no chance", until told that the patient would be accompanied by his personal medical attendant who would take full responsibility for his management. Suitable arrangements would be made for boarding and reception at the other end and, of course, the flight would be first class. Much to their chagrin, I informed my junior staff that this was a job for men not boys; I assembled a bag containing the wherewithal for intubation, various drugs, and a small portable, battery operated, defibrillator. On Day 9 we were ready to depart.
The scene changes to the exotic surroundings of a plush hotel near Heathrow. A meeting had been arranged with the other UK based partners of which I only learned on the way to London and tried to dissuade him from attending. My worst fears were then realised. Far from being amicable, the meeting became increasingly acrimonious over the amount of commission to be paid to each participant. No agreement could be reached and I became concerned about the effects of catecholamine release on my patient's (and my own) myocardium. The main participants were eventually separated by a lawyer and we retired to eat and rest. The following morning we departed for Cairo-an uneventful but truly luxurious flight-and arrived to a hero's welcome. My patient was engulfed by various members of his large family and greeted effusively. We then embarked in a fleet of limousines for the centre of Cairo-a hair-raising and high speed experience which anyone familiar with travelling in that city will know. With immense relief I delivered him safe, sound and asymptomatic to the Cardiac Institute and his local cardiologist.
This should have been the end of the story, but X was keen for me to stay on for a time and I accompanied him the next day (Day 11) to a major bank where he had to negotiate exhaustively, but eventually successfully, with the manager over the massive loan. A pleasant interlude sightseeing was followed by an emergency call in the early hours of the morning to a nursing home where he was now in mild left ventricular failure; I administered morphine intramuscularly and frusemide intravenously and he recovered. He was then well enough to insist that I visited some of the marvels of ancient Thebes, and I spent an unforgettable two days visiting the Temples of Karnak and the valleys and tombs of the Kings and Queens, flying home on Day 17. It was perhaps the strange combination of medical hazard and a glimpse into the turbulent world of high finance which made this trip seem more like a month than the actual week it spanned. On my return colleagues were singularly unimpressed by my trip to Cairo; they thought I had been visiting Caerau, a small mining village near Bridgend! Epilogue Sadly the building project was never completed. X continued to smoke heavily and to work 12 hours a day. Some years later he had coronary artery bypass grafting performed in London. We keep in touch, indeed he was in London only recently with a sick grandchild. He is well.
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